Consensus Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Real-time Estimate Cboe BZX Other stock markets 02:55:24 2024-05-09 pm EDT			5-day change	1st Jan Change
27.32 ^USD	+4.82%		+6.99%	+202.40%

May. 08	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1	MT
May. 08	Avidity's Lead Program Gets FDA Breakthrough Designation	DJ

Evolution of the average Target Price on Avidity Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3ecdd37be84e45f5fb6504a61ff293e5.f1M9hR4fBrQ8sVuZshTVccwhPTFCusb9roDZnZDRwgQ.JwdZ8mdQX9Zv8DzK7SG0HagWDAIgiq3E4dCw1uelrGUUK170S21e52vnFg~b5a8256c41bfa3203bed8539af9025ac

Analyst Recommendations on Avidity Biosciences, Inc.

Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	Apr. 04	MT
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	Apr. 04	MT
Cantor Fitzgerald Starts Avidity Biosciences With Overweight Rating, $60 Price Target	Mar. 14	MT
Chardan Ups Price Target on Avidity Biosciences to $33 From $23 on Efficacy, Safety DM1 Data, Keeps Buy Rating	Mar. 05	MT
Chardan Trims Price Target on Avidity Biosciences to $23 From $27, Keeps Buy Rating	23-08-09	MT
Evercore ISI Upgrades Avidity Biosciences to Outperform From In Line, Price Target is $20	23-05-22	MT
Wells Fargo Adjusts Price Target on Avidity Biosciences to $50 From $55, Maintains Overweight Rating	23-05-11	MT
Credit Suisse Lowers Avidity Biosciences' PT to $30 From $35 After Announced Partial Clinical Hold on AOC 1001 Trial; Keeps Outperform Rating	23-03-31	MT
Evercore ISI Group Downgrades Avidity Biosciences to In Line From Outperform, Price Target is $20	23-03-31	MT
Wells Fargo Adjusts Price Target on Avidity Biosciences to $55 From $60, Maintains Overweight Rating	23-01-04	MT
Credit Suisse Adjusts Price Target on Avidity Biosciences to $35 From $33 After 'Largely Positive Interim Update' on Drug Trial, Keeps Outperform Rating	22-12-15	MT
Raymond James Adjusts Avidity Biosciences Price Target to $71 From $30, Maintains Strong Buy Rating	22-12-15	MT
Stocks Remain Relatively Flat as Investors Wait for Fed Rate-Hike Move	22-12-14	MT
Credit Suisse Adjusts Avidity Biosciences' Price Target to $33 From $32, Keeps Outperform Rating	22-11-09	MT
Raymond James Adjusts Price Target on Avidity Biosciences to $30 From $29, Maintains Strong Buy Rating	22-11-09	MT
Chardan Research Adjusts Price Target for Avidity Biosciences to $27 From $29, Maintains Buy Rating	22-09-27	MT
Avidity Biosciences Shares Slide on Partial FDA Study Hold	22-09-27	DJ
Avidity Biosciences Shares Rise After Chardan Research Initiates Coverage	22-07-20	MT
Chardan Research Initiates Coverage on Avidity Biosciences With Buy Rating, $29 Price Target	22-07-20	MT
Raymond James Starts Avidity Biosciences at Strong Buy With $29 Price Target	22-07-12	MT
SVB Securities Adjusts Avidity Biosciences' Price Target to $50 from $53, Keeps Outperform Rating	22-05-11	MT
Credit Suisse Lowers Avidity Biosciences' Price Target to $32 from $36, Keeps Outperform Rating	22-05-11	MT
Avidity Biosciences Jumps 11% in Pre-Market After SVB Leerink Price Target Upgrade to $53 From $36 With Outperform Rating	21-12-13	MT
SVB Leerink Adjusts Avidity Biosciences' Price Target to $53 from $36, Keeps Outperform Rating	21-12-10	MT
AVIDITY BIOSCIENCES : Evercore ISI Starts Avidity Biosciences at Outperform with $50 Price Target	21-09-07	MT